Item 8.01 Other Events
On April 8, 2022, Seagen Inc. ("Seagen") issued a press release announcing that
a jury in the U.S. District Court for the Eastern District of Texas found that
Daiichi Sankyo Co. Ltd. infringed Seagen's U.S. Patent No. 10,808,039 by selling
in the United States its ENHERTU® product (trastuzumab deruxtecan; DS-8201). The
press release is attached as Exhibit 99.1 to this current report and is
incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release of Seagen Inc. dated April 8, 2022
104 Cover Page Interactive Data File (formatted in Inline XBRL)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses